One of oncology's biggest challenges is that the same treatment can work well for some patients but fail completely in others. A study published in Nature Communications, by a multidisciplinary team ...

Ovarian cancer (OC) is a "silent killer" with an annual incidence of 11.2 per 100,000 and mortality of 7.6 per 100,000. Most cases are diagnosed at ...

A new study sheds light on why promising cancer treatments can produce dramatically different results across patients.

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved the MyChoice ® CDx ...

A discovery from Mayo Clinic researchers in Rochester shows a certain lung cancer treatment can also be used to treat aggressive cases of ovarian cancer. The study published by clinic researchers in ...

Myriad Genetics received approval for a diagnostic test aimed at identifying advanced ovarian cancer patients eligible for treatment with Zejula from the Food and Drug Administration.

One of oncology's biggest challenges is that the same treatment can work well for some patients but fail completely in others. A study published in ...

One of oncology's biggest challenges is that the same treatment can work well for some patients but fail completely in others.

A self-acupressure app helped nearly 60% of women with ovarian cancer no longer experience cancer-related fatigue.The MeTime ...

In A Nutshell A natural compound in grapes, resveratrol, can bind to key ovarian cancer proteins in computer models. Lab studies suggest it may slow tumor growth, reduce inflammation, and boost ...

Myriad Genetics receives US FDA approval for MyChoice CDx test as companion diagnostic for Zejula for patients with ovarian cancer: Salt Lake City Thursday, March 19, 2026, 15:00 ...

Her brain, she tells SELF, “was like scrambled eggs.” She was in the throes of menopause symptoms that she’d expected to have ...